Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved…
Browsing: Acute Lymphoblastic Leukemia
Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of…
Genetic analysis of biopsies taken from the primary tumour, brain metastases and normal tissues of 104 adults with cancer found…
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses…
At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY,…
NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 12 metastatic…
RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the…
The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the…
At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet,…
CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment,…
Comparisons of cancer patients survival and care in Europe up to 2007 showed that although more patients are surviving for…
METEOR, a phase 3 clinical trial, compared cabozantinib, a novel receptor tyrosine kinase inhibitor, with everolimus for the treatment of…
The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle…
Dr. Hamilton appeared on Fox & Friends to discuss a new treatment option for HER2+ breast cancer, an aggressive form…
Dr. Bendell appeared on MSNBC to discuss former U.S. president Jimmy Carter’s melanoma diagnosis. Dr. Bendell discusses breakthroughs in treatment…
Dr. John Hainsworth of the Sarah Cannon Research Institute explains the different types of non-Hodgkin’s lymphoma.
Dr. Skip Burris on This Hour with Berman and Michael on CNN discussing cancer research in 2014.
Our physician experts appeared on Fox and Friends on 4/29 to discuss exciting new developments on the war on cancer.…
Dr. David Spigel on @FoxNews discussing exciting developments in #immunotherapy at the Annual ASCO Meeting
Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute,…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and…
Saad Z. Usmani, MD Levine Cancer Institute – Morehead Charlotte, North Carolina, USA SWOG 1211: A randomized phase I/II study…
Henk Lokhorst, MD University Medical Center Utrecht Utrecht, the Netherlands Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with…
Gunjan L. Shah, MD Tufts Medical Center Oncology Boston Massachusetts, USA Survival benefit and cost of autologous hematopoietic stem cell…
David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA MM-014: A phase 2 trial evaluating efficacy, safety, and…
David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA A phase 1 (Ph1) trial of MK-3475 combined with…
David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA A phase I study of carfilzomib, lenalidomide, vorinostat, and…
David Siegel, MD John Theurer Cancer Center Hackesack, New Jersey, USA Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the…
Torben Plesner, MD Department of Hematology, Vejle Hospital Vejle, Denmark Daratumumab (DARA) (HuMax-CD38), a human IgG1? monoclonal antibody effectively mediates…
Matthias Weiss, MD Marshfield Clinic Marshfield, Wisconsin, USA ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the…
Jeremy Larsen, MD Mayo Clinic Rochester, Minnesota, USA Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA DETERMINATION trial: A phase III multi-center study examining the timing of…
Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone…
Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone…
Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Treatment with immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) has…
Angela Dispenzieri, MD Mayo Clinic Rochester, Minnesota, USA Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy (n.b., using modified measles…
Xin Shelley Wang, MD MD Anderson Cancer Center Houston, Texas, USA Prevalence of high symptom burden and its impact on…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United…
Saad Z. Usmani, MD Levine Cancer Institute – Morehead Charlotte, North Carolina, USA Continuous lenalidomide (LEN) therapy versus observation following…
Thomas G. Martin, MD University of California SF San Francisco, California, USA A phase Ib dose escalation trial of SAR650984…